Clinical trials: Dalteparin
Thrombosis, Venous
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).
- Trial name
- NCT00312013
- Testing
- Nadroparin
- Where
- 95 sites in Belgium, Canada and 9 more
- Volunteers
- 503 people
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
The purpose of this study is to compare the efficacy and safety of dalteparin vs unfractionated heparin for the prevention of VTE (Venous Thromboembolism) in hospitalized acutely ill medical patients.
- Trial name
- NCT00445328
- Testing
- Dalteparin (Fragmin), Unfractionated heparin
- Where
- 7 sites in India
- Volunteers
- 84 people
- Sponsor
- Pfizer
Coronary Artery Disease, Acute Myocardial Infarction
LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin
To prospectively evaluate the utility of enoxaparin vs. oral warfarin in reduction of echocardiographic indices of LV mural thrombus. The primary outcome is the presence of LV mural thrombus at 3.5 months.
- Trial name
- NCT00321009
- Testing
- Enoxaparin
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Corewell Health East
Venous Thromboembolism
Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing
The purpose of this study is to evaluate the safety and efficacy of therapeutic anticoagulation with tinzaparin during pregnancy via weight-based dosing.
- Trial name
- NCT00851864
- Testing
- Tinzaparin
- Where
- Canada
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Heparin Induced Thrombocytopenia (HIT)
Heparin Induced Thrombocytopenia: Pharmacoeconomics
Patients at BWH receiving unfractionated heparin or enoxaparin who subsequently develop heparin induced thrombocytopenia will be identified via a computer generated report designed for the purposes of this study.
- Trial name
- NCT00456001
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Brigham and Women's Hospital
Covid19
Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)
CORONA is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents…
- Trial name
- CORONA (NCT04518735)
- Testing
- Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19
- Where
- Spain
- Volunteers
- 1,707 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Chronic Renal Failure
Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure
The primary objective of the study was to assess the safety in use of the drug Heparin Sodium, produced by Cristália Laboratory, compared drug Liquemine ®, manufactured by Roche Laboratory, and secondary purpose was to evaluate…
- Trial name
- heparin (NCT00828776)
- Testing
- Heparin sodic - Cristália, heparin - Liquemine (Roche)
- Where
- Brazil
- Volunteers
- 62 people
- Sponsor
- Azidus Brasil
Metastatic Pancreatic Cancer
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
People with primary metastatic pancreatic cancer will be treated with nab-paclitaxel and gemcitabine in combination with an investigational agent called necuparanib (M402).
- Trial name
- NCT01621243
- Testing
- nab-paclitaxel, gemcitabine, Necuparanib
- Where
- 37 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Momenta Pharmaceuticals, Inc.
Diabetes Mellitus, Hemodialysis
Effects of Tinzaparin on Cardio-vascular Outcomes and on Blood Lipids in Diabetic Patients on Chronic Hemodialysis
Low molecular weight heparin (LMWH) provides a safe and effective alternative to UFH for hemodialysis anticoagulation. While unfractionated (UF) heparin has been implicated in hyper-lipidemia, the effect of LMWHs on the lipid…
- Trial name
- NCT00407641
- Testing
- Tinzaparin administration, Heparin administration
- Where
- 13 sites in Romania
- Sponsor
- Anemia Working Group Romania
Anticoagulant, Venous Thromboembolism
Study of Low Molecular Weight Heparins
DANHEP is a cluster randomized study of two different low molecular weight heparins. Parenteral anticoagulants are used in a variety of settings, including treatment and prevention of venous thromboembolism in cancer patients…
- Conditions
- Anticoagulant, Venous Thromboembolism, Prophylaxis, Treatment
- Trial name
- DANHEP (NCT06020560)
- Testing
- Dalteparin Prefilled Syringe, Tinzaparin profiled syringe
- Where
- 9 sites in Denmark
- Volunteers
- 65,000 people
- Sponsor
- Herlev Hospital
Kidney Failure, Chronic
Use of Tinzaparin for Anticoagulation in Hemodialysis
The HEMO-TIN trial is designed to look at both the safety (bleeding risk) and effectiveness (clotting risk) of tinzaparin compared with unfractionated heparin for anticoagulation in hemodialysis patients.
- Trial name
- HEMO-TIN (NCT01930396)
- Testing
- Tinzaparin, Unfractionated Heparin
- Where
- Canada
- Volunteers
- 191 people
- Sponsor
- Christine Ribic
Venous Thromboembolism, Neoplasms
Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
Background Patients with cancer and a first deep venous thrombosis of the leg or pulmonary embolism (venous thromboembolism, VTE) are generally treated with low molecular weight heparin (LMWH)injections for 6 months, since this…
- Trial name
- Longheva (NCT01164046)
- Testing
- low molecular weight heparin, vitamin K antagonists
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 56 people
- Sponsor
- University Medical Center Groningen
Embolic Stroke
Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin in Stroke
Patients with Atrial fibrillation (AF) make a unique group of ischemic stroke, mostly caused by emboli from the left atrial appendage.
- Trial name
- NCT02159287
- Testing
- Enoxaparin, Heparin
- Where
- 2 sites in Iran
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shiraz University of Medical Sciences
Proliferative Vitreoretinopathy
The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR
To evaluate the effect of combined 5-FU and low molecular weight heparin in infusion on the rate of retinal redetachment after silicone oil removal in cases of proliferative vitreoretinopathy (PVR).
- Trial name
- NCT00371020
- Testing
- low molecular weight heparin, 5-FU
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
CVD - Cardiovascular Disease, Bruise
The Effect of Standardizing Procedures for SC Injections of LMWH on Patients With CVD
Improper subcutaneous administration of LMWH may cause complications at the injection site. Standardized protocol for subcutaneous LMWH injections in patient with cardiovascular diseases is warranted to ensure consistent best…
- Conditions
- CVD - Cardiovascular Disease, Bruise, Pain
- Trial name
- LMWH (NCT06776159)
- Testing
- Active Control, Standardized injection protocol
- Where
- Hong Kong
- Volunteers
- 180 people
- Sponsor
- The Hong Kong Polytechnic University
Cervical Cancer, Chronic Myeloproliferative Disorders
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
RATIONALE: The use of dalteparin may be able to prevent complications caused by the use of a catheter to supply chemotherapy to cancer patients. It is not yet known if dalteparin is effective in reducing these complications.
- Conditions
- Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00006083
- Testing
- Fragmin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Bariatric Surgery, Anti-Xa Activity
The OAT Trail: The Obesity Anti-Coagulation Thromboprophylaxis Trial.
Blood clots in the legs or lungs (called venous thromboembolism or VTE) are one of the most serious complications after weight loss surgery.
- Conditions
- Bariatric Surgery, Anti-Xa Activity, VTE (Venous Thromboembolism), Obesity & Overweight
- Trial name
- The OAT-RCT (NCT07559643)
- Testing
- Anti-Xa Activity Monitoring, Tinzaparin (Leo), enoxaparin
- Where
- Ireland
- Volunteers
- 180 people
- Sponsor
- University College Dublin
COVID-19, Deep Vein Thrombosis
Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.
To see whether our increased dosing regimen of unfractionated heparin (UF) and low molecular weight heparin (LMWH) in COVID-19 patients was effective at preventing thrombo-embolic complications.
- Conditions
- COVID-19, Deep Vein Thrombosis, Anticoagulants and Bleeding Disorders, Critical Illness
- Trial name
- NCT05224388
- Testing
- Enoxaparin, Heparin
- Where
- Belgium
- Volunteers
- 813 people
- Sponsor
- University Hospital, Ghent
Critical Illness, Therapeutic Drug Monitoring
Anti-Xa Level With Thromboprophylactic Dosage Nadroparin in Critically Ill COVID-19 and Non-COVID-19 Patients
Primary objective The objective of this study is to compare anti-Xa levels obtained with a standard high dose thrombosis prophylaxis in COVID-19 intensive care-patients compared with anti-Xa levels obtained with a normal dose…
- Conditions
- Critical Illness, Therapeutic Drug Monitoring, Venous Thromboembolism
- Trial name
- NADRO (NCT05926518)
- Testing
- blood sampling
- Where
- Netherlands
- Volunteers
- 62 people
- Sponsor
- Rijnstate Hospital
Cancer, Atrial Fibrillation
Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)
The primary objective is to assess the safety and efficacy of switching from direct oral anticoagulants to low molecular weight heparin in cancer patients during antineoplastic therapy
- Trial name
- MAFIC (NCT04508855)
- Testing
- Low molecular weight heparin
- Where
- 2 sites in Greece
- Sponsor
- AHEPA University Hospital